Literature DB >> 18223490

A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution.

Takashi Toyama1, Naoki Hiramatsu, Takayuki Yakushijin, Tsugiko Oze, Fumihiko Nakanishi, Masakazu Yasumaru, Kiyoshi Mochizuki, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi.   

Abstract

OBJECTIVE: To manage hepatocellular carcinoma (HCC) patients surviving for a long term, the treatment strategy for recurrent cancer is as important as that for the initial treatment. However, no prognostic scoring system has been available for patients with HCC recurrence. The purpose of this study was to develop a new staging system for deciding the treatment strategy not only for first-time diagnosed patients but also for recurrent patients.
METHODS: A total of 861 cases diagnosed at our single institution from 1993 to 2003 were included. Overall survival was the only end point. The Cox model was used for multivariate analyses.
RESULTS: As of August 2004, 344 cases (59%) had died. Overall median survival time was 41 months. For multivariate Cox regression analysis, independent predictive factors of survival were the number of recurrences, the Child-Pugh score, 3 nodules less than 3 cm and none of vascular invasion, and the alpha-fetoprotein level. A simple scoring system was thus developed, assigning scores (0/1) to the 4 covariates of the final model. Compared with the other scoring systems, the new scoring system has a greater discriminant ability.
CONCLUSIONS: We concluded that our scoring system can serve as a new prognostic system that reflects the spread of HCC, treatment response, and liver function. It should be very useful as the only method which can be applied for patients with recurrence.

Entities:  

Mesh:

Year:  2008        PMID: 18223490     DOI: 10.1097/MCG.0b013e3180ebe790

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  10 in total

1.  Proposal of new classification for postoperative patients with hepatocellular carcinoma based on tumor growth characteristics.

Authors:  Cui-Hong Zhu; Xiao-Hui Liu; Rui Cao; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test.

Authors:  Yusuke Suzuki; Kenji Imai; Koji Takai; Tatsunori Hanai; Hideki Hayashi; Takafumi Naiki; Yoichi Nishigaki; Eiichi Tomita; Masahito Shimizu; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-15       Impact factor: 4.553

3.  A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma.

Authors:  Bai-Hong Zhang; Xiang-Hui Wang; Hong-Yun Yue; Chang-Quan Ling
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-15       Impact factor: 4.553

Review 4.  Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

5.  The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma.

Authors:  Makoto Chuma; Shuhei Hige; Toshiya Kamiyama; Takashi Meguro; Atsushi Nagasaka; Kazuaki Nakanishi; Yoshiya Yamamoto; Mitsuru Nakanishi; Toshihisa Kohara; Takuya Sho; Keiko Yamamoto; Hiromasa Horimoto; Tomoe Kobayashi; Hideki Yokoo; Michiaki Matsushita; Satoru Todo; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2009-06-25       Impact factor: 7.527

6.  Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy.

Authors:  Zu-Sen Wang; Li-Qun Wu; Xin Yi; Chao Geng; Yu-Jun Li; Ru-Yong Yao
Journal:  BMC Cancer       Date:  2013-06-24       Impact factor: 4.430

7.  Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment.

Authors:  Naoki Watanabe; Koji Takai; Kenji Imai; Masahito Shimizu; Takafumi Naiki; Masahito Nagaki; Hisataka Moriwaki
Journal:  J Clin Biochem Nutr       Date:  2011-10-29       Impact factor: 3.114

8.  An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy.

Authors:  Yukio Tokumitsu; Takao Tamesa; Satoshi Matsukuma; Noriaki Hashimoto; Yoshinari Maeda; Yoshihiro Tokuhisa; Kazuhiko Sakamoto; Tomio Ueno; Shoichi Hazama; Hiroyuki Ogihara; Yusuke Fujita; Yoshihiko Hamamoto; Masaaki Oka; Norio Iizuka
Journal:  Int J Oncol       Date:  2014-12-17       Impact factor: 5.650

9.  Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection.

Authors:  Min Zhang; Dexin Wang; Haidong Liu; Hui Li
Journal:  Infect Agent Cancer       Date:  2018-06-08       Impact factor: 2.965

Review 10.  Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis.

Authors:  Peng Yuan; Peng Chen; Yeben Qian
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.